K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · JOHNSON & JOHNSON SERVICES INC.
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | TODD STRATEGY GROUP | $100K | Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864: HELP Copays Act. Inflation Reduction Act Implementation. |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE NICKLES GROUP, LLC | $80K | Issues related to mental health. Monitored Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Issues related to drug pricing. Issues related to ingredient safety. Implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Issues related to pharmacy benefit management. Monitored issues related to Medicare physician payment. Issues related to Most Favored Nation drug pricing. Monitor implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate and international taxes. Issues related to litigation reform. Issues related to tariffs. |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | FULCRUM PUBLIC AFFAIRS LLC | $60K | Issues related to public health, science and technology, sustainability, innovation, and competition. Issues related to public health, science and technology, sustainability, innovation, and competition. |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | ML STRATEGIES, LLC | $50K | Issues related to cardiovascular health; H.R.5343 / S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025; issues related to Heart Recovery Awareness Day and H. Res. 1301, designating February 20th Heart Recovery Awareness Day |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | SPLITOAK STRATEGIES LLC | $50K | Value of prescription drugs and patient access Issues related to Medicare Parts B & D, MFN Promoting U.S. competitiveness while ensuring U.S. leadership role in developing medicines |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BECKER & POLIAKOFF, P.A. | $30K | Educating members and staff on the company's presence in their districts and states and contributions to the wellbeing and health of their constituents. |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE COMPLETE AGENCY | $30K | Issues such as infant & maternal mortality, global pandemics, climate change & sustainability. |
| 2026-04-19 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to patient access Issues related to patents Legislation related to competition and intellectual property issues Drug pricing Issues related to corporate and international tax Research and development costs P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation Issues related to civil justice reform, including third party litigation funding reform Trade and tariffs affecting the pharmaceutical industry |
| 2026-03-04 | JNJ | JOHNSON & JOHNSON SERVICES INC. | FULCRUM PUBLIC AFFAIRS LLC | $60K | Issues related to public health, science and technology, sustainability, innovation, and competition. Issues related to public health, science and technology, sustainability, innovation, and competition. |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE NICKLES GROUP, LLC | $70K | Issues related to mental health. Issues related to SUPPORT Act Reauthorization. Monitored Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Issues related to drug pricing. Issues related to ingredient safety. Implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to Ambulatory Surgical Centers. Issues related to pharmacy benefit management. Monitored issues related to Medicare physician payment. Issues related to Most Favored Nation drug pricing. Monitor implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate and international taxes. Issues related to litigation reform. Issues related to tariffs. |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | FULCRUM PUBLIC AFFAIRS LLC | $60K | Issues related to public health, science and technology, sustainability, innovation, and competition. Issues related to public health, science and technology, sustainability, innovation, and competition. |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | TODD STRATEGY GROUP | $60K | Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation. |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | ML STRATEGIES, LLC | $50K | Issues related to cardiovascular health; H.R.5343 / S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025; issues related to Heart Recovery Awareness Day and H. Res. 1301, designating February 20th Heart Recovery Awareness Day |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | SPLITOAK STRATEGIES LLC | $50K | Value of prescription drugs and patient access Issues related to Medicare Parts B & D P.L. 119-21 H.R. 946/S. 1862, ORPHAN Cures Act H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025/Public Law No: 119-44 Promoting U.S. competitiveness while ensuring U.S. leadership role in developing medicines |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE COMPLETE AGENCY | $30K | Issues such as infant & maternal mortality, global pandemics, climate change & sustainability. |
| 2026-01-19 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to patient access Issues related to patents Legislation related to competition and intellectual property issues Drug pricing Issues related to corporate and international tax Research and development costs P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation Issues related to civil justice reform, including third party litigation funding reform Trade and tariffs affecting the pharmaceutical industry |
| 2026-01-17 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BECKER & POLIAKOFF, P.A. | $30K | Educating members and staff on the company's presence in their districts and states and contributions to the wellbeing and health of their constituents. |
| 2025-10-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | FULCRUM PUBLIC AFFAIRS LLC | $60K | Issues related to public health, science and technology, sustainability, innovation, and competition. Issues related to public health, science and technology, sustainability, innovation, and competition. |
| 2025-10-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE NICKLES GROUP, LLC | $50K | H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act and pharmacy benefit management. Issues related to mental health. Issues related to SUPPORT Act Reauthorization. Monitored Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Issues related to drug pricing. Issues related to ingredient safety. Implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to Ambulatory Surgical Centers. Issues related to pharmacy benefit management. Monitored issues related to Medicare physician payment. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act and issues related to drug pricing. Issues related to Most Favored Nation drug pricing. H.R. 946 / S. 1862, ORPHAN Cures Act. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate and international taxes. |
| 2025-10-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | SPLITOAK STRATEGIES LLC | $50K | Value of prescription drugs and patient access Issues related to Medicare Parts B & D P.L. 119-21 H.R. 946/S. 1862, ORPHAN Cures Act H.R. 2483, SUPPORT Act Issues related to - H.R. 1109, the Litigation Transparency Act of 2025, and transparency in domestic third-party litigation funding - the Protecting Our Courts from Foreign Manipulation Act, and transparency in foreign third-party litigation funding |
| 2025-10-17 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to patient access Issues related to patents Legislation related to competition and intellectual property issues Drug pricing Issues related to corporate and international tax Research and development costs H.R.1 Implementation Issues related to civil justice reform, including third party litigation funding reform Trade and tariffs affecting the pharmaceutical industry |
| 2025-10-17 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE COMPLETE AGENCY | $30K | Issues such as infant & maternal mortality, global pandemics, climate change & sustainability. |
| 2025-10-17 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BECKER & POLIAKOFF, P.A. | $30K | Educating members and staff on the company's presence in their districts and states and contributions to the wellbeing and health of their constituents. |
| 2025-10-12 | JNJ | JOHNSON & JOHNSON SERVICES INC. | TODD STRATEGY GROUP | $60K | Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation. |
| 2025-10-11 | JNJ | JOHNSON & JOHNSON SERVICES INC. | SPLITOAK STRATEGIES LLC | $50K | Value of prescription drugs Issues related to Medicare Parts B & D Implementation of P.L. 117-169, Inflation Reduction Act of 2022 |
| 2025-07-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | FULCRUM PUBLIC AFFAIRS LLC | $60K | Issues related to public health, science and technology, sustainability, innovation, and competition. Issues related to public health, science and technology, sustainability, innovation, and competition. |
| 2025-07-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | SPLITOAK STRATEGIES LLC | $50K | Value of prescription drugs and patient access Issues related to Medicare Parts B & D P.L. 119-21 H.R. 946/S. 1862, ORPHAN Cures Act H.R. 2483, SUPPORT Act |
| 2025-07-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BECKER & POLIAKOFF, P.A. | $30K | Educating members and staff on the company's presence in their districts and states and contributions to the wellbeing and health of their constituents. |
| 2025-07-19 | JNJ | JOHNSON & JOHNSON SERVICES INC. | TODD STRATEGY GROUP | $60K | Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation. |
| 2025-07-18 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to patient access Issues related to patents Legislation related to competition and intellectual property issues Drug pricing Issues related to corporate and international tax Research and development costs H.R.1 One Big Beautiful Bill Issues related to civil justice reform, including third party litigation funding reform Trade and tariffs affecting the pharmaceutical industry |
| 2025-07-18 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE COMPLETE AGENCY | $30K | Issues such as infant & maternal mortality, global pandemics, climate change & sustainability. |
| 2025-07-17 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE NICKLES GROUP, LLC | $50K | H.R. 1, One Big Beautiful Bill Act and pharmacy benefit management. Issues related to mental health. Issues related to SUPPORT Act Reauthorization. Monitored Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Issues related to drug pricing. Issues related to ingredient safety. Implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to Ambulatory Surgical Centers. Issues related to pharmacy benefit management. Monitored issues related to Medicare physician payment. H.R. 1, One Big Beautiful Bill Act and issues related to drug pricing. Issues related to Most Favored Nation drug pricing. H.R. 946 / S. 1862, ORPHAN Cures Act. H.R. 1, One Big Beautiful Bill Act, as it relates to corporate and international taxes. Issues related to litigation reform. |
| 2025-06-26 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE NICKLES GROUP, LLC | $50K | Issues related to mental health. Issues related to SUPPORT Act reauthorization. Monitored Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Monitored issues related to drug pricing. H.R. 1968 (P.L. 119-4), Full-Year Continuing Appropriations and Extensions Act, 2025. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to Ambulatory Surgical Centers. Issues related to pharmacy benefit management. Monitored issues related to Medicare physician payment. H.R. 1968 (P.L. 119-4), Full-Year Continuing Appropriations and Extensions Act, 2025. H.R. 1990, the American Innovation and R&D Competitiveness Act, and issues related to the R&D tax credit. Issues related to the extension of the 2017 Tax Cut and Jobs Act provisions, and corporate and in |
| 2025-04-30 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to patient access Issues related to patents Legislation related to competition and intellectual property issues Drug pricing Issues related to corporate and international tax Research and development costs Issues related to civil justice reform, including third party litigation funding reform |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | TODD STRATEGY GROUP | $60K | Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation. |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | FULCRUM PUBLIC AFFAIRS LLC | $60K | Issues related to public health, science and technology, sustainability, innovation, and competition. Issues related to public health, science and technology, sustainability, innovation, and competition. |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | SPLITOAK STRATEGIES LLC | $50K | H.R.2483, SUPPORT for Patients and Communities Reauthorization Act of 2025; H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE NICKLES GROUP, LLC | $40K | Issues related to mental health. Issues related to SUPPORT Act reauthorization. Monitored Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Monitored issues related to drug pricing. H.R. 1968 (P.L. 119-4), Full-Year Continuing Appropriations and Extensions Act, 2025. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to Ambulatory Surgical Centers. Issues related to pharmacy benefit management. Monitored issues related to Medicare physician payment. H.R. 1968 (P.L. 119-4), Full-Year Continuing Appropriations and Extensions Act, 2025. H.R. 1990, the American Innovation and R&D Competitiveness Act, and issues related to the R&D tax credit. Issues related to the extension of the 2017 Tax Cut and Jobs Act provisions, and corporate and in |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE COMPLETE AGENCY | $30K | Issues such as infant & maternal mortality, global pandemics, climate change & sustainability. |
| 2025-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BECKER & POLIAKOFF, P.A. | $30K | Issues related to corporate and international tax. Research and development costs. |
| 2025-04-18 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to patient access Issues related to patents Legislation related to competition and intellectual property issues Drug pricing Issues related to corporate and international tax Research and development costs Issues related to civil justice reform, including third party litigation funding reform |
| 2025-03-24 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BECKER & POLIAKOFF, P.A. | $0 | pharmaceutical, biotechnology, and medical technologies issues |
| 2025-02-04 | JNJ | JOHNSON & JOHNSON SERVICES INC. | SPLITOAK STRATEGIES LLC | $50K | Value of prescription drugs Issues related to Medicare Parts B & D Implementation of P.L. 117-169, Inflation Reduction Act of 2022 H.R.4531/S.3393 - Support for Patients and Communities Reauthorization Act - pharmacy delivery to administering practitioners |
| 2025-01-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | FULCRUM PUBLIC AFFAIRS LLC | $60K | Issues related to public health, science and technology, sustainability, innovation, and diversity and inclusion issues, and competition. Issues related to public health, science and technology, sustainability, innovation, and diversity and inclusion issues, and competition. |
| 2025-01-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | TODD STRATEGY GROUP | $60K | Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.1375/HR 830 - HELP Copays Act. Inflation Reduction Act Implementation. |
| 2025-01-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE NICKLES GROUP, LLC | $40K | Issues related to mental health. Issues related to SUPPORT Act reauthorization. Monitored S. 2333, Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Monitored issues related to drug pricing. H.R. 10445, Furthering Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025, as it relates to pharmacy benefit management reforms and SUPPORT Act. H.R. 10545, The American Relief Act of 2025. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to Ambulatory Surgical Centers. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act. Issues related to preventative services. Issues related to pharmacy benefit management. Issues related to the Medicaid Drug Rebate Program. Monitored issues related to Medicare physician payment. |
| 2025-01-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE COMPLETE AGENCY | $30K | Issues such as infant & maternal mortality, global pandemics, climate change & sustainability. |
| 2025-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to patient access Issues related to patents Legislation related to competition and intellectual property issues Drug pricing Issues related to corporate and international tax Research and development costs Issues related to civil justice reform, including third party litigation funding reform |